Pixantrone is a Safe and Effective Therapeutic Option for Elderly Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma in the Real-World Setting

Treatment of Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) remains an unmet need in every day clinical practice. Pixantrone is approved by European Medicines Agency (EMA) for R/R DLBCL last generation anthracenedione developed to reduce the risk cardiotoxicity. However real-world data regarding efficacy and safety this agent are limited controversial. In our study we analyzed 13 heavily pretreated elderly patients who were treated with at least 1 cycle pixantrone. The overall response rate was 46%; 3 achieved complete had partial remission. All responders anthracycline sensitive as they responded anthracycline-based regimens upfront. Four extranodal involvement (skin: 2, oropharynx: 1, oral cavity:1). Interestingly, displayed long remission after first line therapy (87, 62 37 months, respectively). Regarding well tolerated there no treatment discontinuation due Adverse Events. Our results indicate that effective safe patients. Further studies warranted identify subgroup may benefit from pixantrone optimum positioning drug DLBCL.